1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的药学监护

李惟妙; 宋荣景; 张春燕; 黄琳; 张晓红

doi:10.6039/j.issn.1001-0408.2024.18.21

您当前的位置：

首页 >

文章列表页 >

1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的药学监护

药师与药学服务 | 更新时间：2024-09-25

- 1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的药学监护
- Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation
- 中国药房 2024年35卷第18期页码：2310-2314
- 作者机构：
  
  1.北京大学人民医院药学部，北京　100044
  2.北京大学药学院，北京　100191
- 作者简介：
  
  药师，硕士研究生。研究方向：临床药学。E-mail：liweimiaotju@163.com
  主管药师，博士。研究方向：临床药学、医院药学。 E-mail：songrongjing2008@163.com
- 基金信息：
  
  北京大学人民医院研究与发展基金资助项目(RDY2021-28)
- DOI：10.6039/j.issn.1001-0408.2024.18.21
  中图分类号： R969.3
- 纸质出版日期：2024-09-30，
  
  收稿日期：2024-05-12，
  
  修回日期：2024-08-14，
- 稿件说明：
移动端阅览
李惟妙,宋荣景,张春燕等.1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的药学监护 ^Δ[J].中国药房,2024,35(18):2310-2314.

LI Weimiao,SONG Rongjing,ZHANG Chunyan,et al.Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation[J].ZHONGGUO YAOFANG,2024,35(18):2310-2314.
李惟妙,宋荣景,张春燕等.1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的药学监护 ^Δ[J].中国药房,2024,35(18):2310-2314. DOI： 10.6039/j.issn.1001-0408.2024.18.21.

LI Weimiao,SONG Rongjing,ZHANG Chunyan,et al.Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation[J].ZHONGGUO YAOFANG,2024,35(18):2310-2314. DOI： 10.6039/j.issn.1001-0408.2024.18.21.

摘要

目的

为糖尿病合并肝移植术后免疫抑制剂致高脂血症患者的临床合理用药和药学监护提供参考。

方法

临床药师参与1例糖尿病合并疑似肝移植术后免疫抑制剂致高脂血症患者的治疗过程。由于患者血糖控制不佳，临床药师与医生共同调整降糖方案为三餐前分别皮下注射赖脯胰岛素注射液18、12、16单位，睡前皮下注射甘精胰岛素注射液16单位；由于患者发生高脂血症，临床药师结合相关指南并通过梳理其免疫抑制剂剂量调整时间轴及血脂水平变化趋势，明确血脂异常升高的可能诱因为免疫抑制剂，建议给予瑞舒伐他汀钙片5 mg，qd降脂治疗，分别将吗替麦考酚酯胶囊和他克莫司胶囊降至500 mg，bid和2 mg，bid，并开展用药宣教及药学监护。

结果

医生采纳临床药师的建议。患者经治疗后，血糖、血脂水平明显改善，准予带药出院。

结论

临床药师通过建议加用他汀类药物、调整免疫抑制剂剂量、开展药学监护等药学服务手段，优化患者个体化用药方案，保障了患者用药的安全性和有效性。

Abstract

OBJECTIVE

To provide a reference for clinically rational drug use and pharmaceutical care for patients with diabetes complicated with hyperlipidemia induced by immunosuppressive agents after liver transplantation.

METHODS

Clinical pharmacists participated in the treatment of a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation. Due to the poor glucose control of the patient， the clinical pharmacists assisted the doctor in adjusting the glycemic control plan： subcutaneous injection of 18， 12 and 16 units of Insulin lispro injection before meals， and subcutaneous injection of 16 units of Insulin glargine injection before bedtime. Due to the occurrence of hyperlipidemia in the patient， clinical pharmacists clarified the possible cause of abnormal blood lipid elevation was using immunosuppressants by reviewing the timeline of dose adjustment of immunosuppressive agents and changes in blood lipid levels based on relevant guidelines. Clinical pharmacists suggested using Rosuvastatin calcium tablets 5 mg， qd for lipid-lowering treatment， reducing the dosage of Mycophenolate mofetil capsules and Tacrolimus capsules to 500 mg， bid and 2 mg， bid， respectively. Medication education and pharmaceutical care were also carried out.

RESULTS

The doctor adopted the advice of the clinical pharmacists. After treatment， the levels of blood glucose and blood lipid in the patient improved， and he was allowed to be discharged with medication.

CONCLUSIONS

Clinical pharmacists provide pharmaceutical services such as recommending the addition of statins， adjusting the dosage of immunosuppressive agents， and conducting pharmaceutical care to optimize individualized medication plans for patients and ensure the safety and effectiveness of medication.

关键词

免疫抑制剂肝移植术后高脂血症糖尿病临床药师药学监护

Keywords

after liver trans-plantationhyperlipidemiadiabetesclinical pharmacistpharmaceutical care

references

ADAM R，KARAM V，DELVART V，et al. Evolution of indications and results of liver transplantation in Europe：a report from the European Liver Transplant Registry（ELTR）[J]. J Hepatol，2012，57（3）：675-688.

National Cholesterol Education Program（NCEP）Expert Panel on Detection，Evaluation，and Treatment of High Blood Cholesterol in Adults（Adult Treatment Panel Ⅲ）. Third report of the National Cholesterol Education Program（NCEP）expert panel on detection，evaluation，and treatment of high blood cholesterol in adults（adult treatment panel Ⅲ）final report[J]. Circulation，2002，106（25）：3143-3421.

FORD E S，GILES W H，DIETZ W H. Prevalence of the metabolic syndrome among US adults：findings from the third national health and nutrition examination survey[J]. JAMA，2002，287（3）：356-359.

FORD E S，GILES W H，MOKDAD A H. Increasing prevalence of the metabolic syndrome among U.S. adults[J]. Diabetes Care，2004，27（10）：2444-2449.

GAMI A S，WITT B J，HOWARD D E，et al. Metabolic syndrome and risk of incident cardiovascular events and death：a systematic review and meta-analysis of longitu-dinal studies[J]. J Am Coll Cardiol，2007，49（4）：403-414.

WATT K D，PEDERSEN R A，KREMERS W K，et al. Evolution of causes and risk factors for mortality post-liver transplant：results of the NIDDK long-term follow-up study[J]. Am J Transplant，2010，10（6）：1420-1427.

GOJOWY D，ADAMCZAK M，DUDZICZ S，et al. High frequency of arterial hypertension in patients after liver transplantation[J]. Transplant Proc，2016，48（5）：1721-1724.

中华医学会器官移植学分会. 中国实体器官移植受者血脂管理规范：2019版[J]. 器官移植，2019，10（2）：101-111.

Branch of Organ Transplantation of Chinese Medical Association. Management specification for blood lipid on recipients with solid organ transplantation in China：2019 edition[J].Organ Transplant，2019，10（2）：101-111.

中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识：2019版[J]. 器官移植，2020，11（1）：19-29.

Branch of Organ Transplant Physician of Chinese Medical Doctor Association，Liver Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association.Expert consensus on the management of metabolic di-seases in Chinese liver transplant recipients：2019 edition[J]. Organ Transplant，2020，11（1）：19-29.

中华医学会器官移植学分会.中国肝移植免疫抑制治疗与排斥反应诊疗规范：2019版[J/OL].中华移植杂志（电子版），2019，13（4）：262-268[2024-03-12]. https：//zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2019.04.002https://zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2019.04.002. DOI：10.3877/cma.j.issn.1674-3903.2019.04.002http://dx.doi.org/10.3877/cma.j.issn.1674-3903.2019.04.002.

Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China：2019 edition[J/OL]. Chin J Transplant（Electron Ed），2019，13（4）：262-268[2024-03-12]. https：//zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2019.04.002https://zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2019.04.002. DOI：10.3877/cma.j.issn.1674-3903.2019.04.002http://dx.doi.org/10.3877/cma.j.issn.1674-3903.2019.04.002.

中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南：2021版[J/OL].中华移植杂志（电子版），2021，15（6）：321-328[2024-03-12].https：//zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2021.06.001https://zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2021.06.001. DOI：10.3877/cma.j.issn.1674-3903.2021.06.001http://dx.doi.org/10.3877/cma.j.issn.1674-3903.2021.06.001.

Branch of Organ Transplant Physician of Chinese Medical Doctor Association，Liver Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association.The Chinese clinical practice guidelines on liver transplantation for hepatocellular carcinoma：2021 edition[J/OL]. Chin J Transplant（Electron Ed），2021，15（6）：321-328[2024-03-12]. https：//zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2021.06.001https://zhyzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.1674-3903.2021.06.001. DOI：10.3877/cma.j.issn.1674-3903.2021.06.001http://dx.doi.org/10.3877/cma.j.issn.1674-3903.2021.06.001.

KHOLAIF N，BATHA L，ELMAHI I，et al. Transplantation of heterozygous familial hypercholesterolemia living donor liver resulting in early myocardial infarction：a possible dangerous link[J/OL]. Arch Monaldi Le Malattie Del Torace，2024[2024-03-12]. https：//www.monaldi-archives.org/index.php/macd/article/view/2907https://www.monaldi-archives.org/index.php/macd/article/view/2907. DOI：10.4081/monaldi.2024.2907http://dx.doi.org/10.4081/monaldi.2024.2907.

肖正楠，李俊辉，蒋捷，等. 肝移植术后糖尿病的最新进展[J]. 器官移植，2021，12（5）：630-636.

XIAO Z N，LI J H，JIANG J，et al. Recent progress on diabetes mellitus after liver transplantation[J]. Organ Transplant，2021，12（5）：630-636.

中国血脂管理指南修订联合专家委员会. 中国血脂管理指南：2023年 [J]. 中国循环杂志，2023，38（3）：237-271.

Joint Committee on the Chinese Guidelines for Lipid Mana-gement.Chinese guidelines for lipid management：2023[J]. Chin Circ J，2023，38（3）：237-271.

RAJASEKERAN H，KIM S J，CARDELLA C J，et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes：a case series[J]. Diabetes Care，2017，40（7）：e75-e76.

HEERSPINK H，STEFANSSON BV，CORREA-ROTTER R，et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med，2020，383（15）：1436-1446.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

临床药师参与1例大疱性类天疱疮、肺曲霉病合并播散性皮疽诺卡菌感染治疗的药学实践

多模式镇痛治疗1例儿童原发性红斑性肢痛症伴感染并药学监护 ^Δ

1例Lemierre’s综合征患者的药物治疗分析与监护

1例鹦鹉热衣原体重症肺炎患者的抗感染治疗及药学监护

临床药师参与1例EB病毒性脑炎患者的药学实践